BAM
TVRD

Blueshift Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Blueshift Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-541
Closed -$237K – 1176
2021
Q4 		$237K Buy
+541
New +$272K 0.02% 707
2020
Q1 		– Sell
-344
Closed -$200K – 735
2019
Q4 		$200K Buy
+344
New +$241K 0.02% 723

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Blueshift Asset Management's TVRD Position: Q1 2022 in Review

Blueshift Asset Management sold out of Tvardi Therapeutics (TVRD) in Q1 2022, closing a stake of 541 shares — an estimated $237K sold.

Blueshift Asset Management first reported a position in TVRD in Q4 2019 and held it in 2 quarters. The position peaked at $237K in Q4 2021. 182 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Blueshift Asset Management reported no remaining Tvardi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 541 Tvardi Therapeutics shares in Q1 2022, an estimated $237K.
  • Blueshift Asset Management first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 2 quarters.
  • Blueshift Asset Management's Tvardi Therapeutics position peaked at $237K in Q4 2021.
  • 182 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Blueshift Asset Management's 13F filing for Q1 2022, filed 12 May 2022.